Primary CNS lymphoma

References

• Kadan-Lottick N, Sklusarek M, Gurney J. Decreasing incidence rates of primary central nervous system lymphoma. Cancer95, 193–202 (2002).
   PubMed Web of Science ®Google Scholar
• Bataille B, Delwail V, Menet E et al. Primary intracerebral malignant lymphoma: report of 248 cases. J. Neurosurg.92(2), 261–266 (2000).
   PubMed Web of Science ®Google Scholar
• Newell M, Hoy J, Cooper S et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer100(12), 2627–2634 (2004).
   PubMedGoogle Scholar
• Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann. Intern. Med.119, 1093–1104 (1993).
   PubMed Web of Science ®Google Scholar
• Kuker W, Nagele T, Korfel A et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J. Neuro-Oncol.72(2), 169–177 (2005).
   PubMed Web of Science ®Google Scholar
• Abrey L, Batchelor T, Ferreri A et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J. Clin. Oncol.23(22), 5034–5043 (2005).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Hummel M, Korfel A et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J. Clin. Oncol.24(29), 4754–4757 (2006).
   PubMed Web of Science ®Google Scholar
• Miller DC, Hochberg FH, Harris NL et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958–1989. Cancer74(4), 1383–1397 (1994).
   PubMed Web of Science ®Google Scholar
• Camilleri-Broët S, Crinière E, Broët P et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood107(1), 190–196 (2006).
   PubMed Web of Science ®Google Scholar
• Rubenstein J, Fridlyand J, Shen A et al. Gene expression and angiotropism in primary CNS lymphoma. Blood107(9), 3716–3723 (2006).
   PubMed Web of Science ®Google Scholar
• Meeker TC, Shiramizu B, Kaplan L et al. Evidence for molecular subtypes of HIV-associated lymphoma: division into peripheral monoclonal, polyclonal and central nervous system lymphoma. AIDS5(6), 669–674 (1991).
   PubMed Web of Science ®Google Scholar
• Ferreri A, Blay J, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J. Clin. Oncol.21(2), 266–272 (2003).
   PubMed Web of Science ®Google Scholar
• Abrey L, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: the Memorial Sloan–Kettering Cancer Center prognostic model. J. Clin. Oncol.24(36), 5711–5715 (2006).
   PubMed Web of Science ®Google Scholar
• Braaten K, Betensky R, de Leval L et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin. Cancer Res.9(3), 1063–1069 (2003).
   PubMed Web of Science ®Google Scholar
• Takeshita M, Iwashita A, Kurihara K et al. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am. J. Surg. Pathol.24, 1641–1669 (2000).
   PubMed Web of Science ®Google Scholar
• Ferreri A, Abrey L, Blay J et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J. Clin. Oncol.21(12), 2407–2414 (2003).
   PubMed Web of Science ®Google Scholar
• Lin C, Kuo K, Chuang S et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of the central nervous system origin and peripheral nodal origin. Clin. Cancer Res.12, 1152–1156 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med.346, 1937–1947 (2002).
   PubMed Web of Science ®Google Scholar
• Lossos I, Jones C, Warnke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood98, 945–951 (2001).
   PubMed Web of Science ®Google Scholar
• Takeshita M, Iwashita A, Kurihara K, et al. Histological and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am. J. Surg. Pathol.24, 1641–1669 (2000).
   PubMed Web of Science ®Google Scholar
• Beela MS, Carson K, Grossman SA. Initial response to glucocorticoids: a potentially important prognostic factor in patients with primary CNS lymphoma. Cancer106, 383–387 (2006).
   PubMedGoogle Scholar
• Bellinzona M, Roser F, Ostertag H, Gaab R, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur. J. Surg. Oncol.31(1), 100–105 (2005).
   PubMed Web of Science ®Google Scholar
• Batchelor T, Loeffler J. Primary CNS lymphoma. J. Clin. Oncol.24(8), 1281–1288 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson D, Martz K, Bonner H et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys.23(1), 9–17 (1992).
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Ogino H, Hasegawa M et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int. J. Radiat. Oncol. Biol. Phys.62(3), 809–813 (2005).
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Hasegawa M, Tamaki Y et al. Comparable outcomes of radiation therapy without high-dose methotrexate for patients with primary central nervous system lymphoma. Jpn. J. Clin. Oncol.33(8), 443–449 (2003).
   PubMedGoogle Scholar
• Bessell E, Lopez-Guillermo A, Villa S et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J. Clin. Oncol.20(1), 231–236 (2002).
   PubMed Web of Science ®Google Scholar
• Fisher B, Seiferheld W, Schultz C et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup Phase II combined modality treatment of primary central nervous system lymphoma. J. Neuro-Oncol.74(2), 201–205 (2005).
   PubMed Web of Science ®Google Scholar
• Olson J, Blakeley J, Grossman S et al. Differences in the distribution of methotrexate into high grade gliomas following intraveneous administration as monitored by microdialysis, are associated with blood–brain-barrier integrity. Am. Soc. Clin. Oncol. (2006) (Abstract 1548).
   PubMedGoogle Scholar
• Hiraga S, Arita N, Ohnishi T et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J. Neurosurg.91(2), 221–230 (1999).
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Voss N, Chhanabhai M et al. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency. Cancer103(5), 1008–1017 (2005).
   PubMed Web of Science ®Google Scholar
• DeAngelis L, Seiferheld W, Schold S, Fisher B, Schultz C. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J. Clin. Oncol.20(24), 4643–4648 (2002).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Morii K, Shinbo Y et al. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. Ann. Hematol.84(7), 447–455 (2005).
   PubMed Web of Science ®Google Scholar
• Poortmans P, Kluin-Nelemans H, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J. Clin. Oncol.21(24), 4483–4488 (2003).
   PubMed Web of Science ®Google Scholar
• Dabaja BS, McLaughlin P, Ha CS et al. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. Cancer98(5), 1021–1028 (2003).
   PubMedGoogle Scholar
• Hodson D, Bowles K, Cooke L et al. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases. Clin. Oncol. (R. Coll. Radiol.)17(3), 185–191 (2005).
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O’Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiation therapy: a report of the NABTT 96–07. J. Clin. Oncol.21(6), 1044–1049 (2003).
   PubMed Web of Science ®Google Scholar
• Ng S, Rosenthal M, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro-Oncology2(1), 40–44 (2000).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter Phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J. Clin. Oncol.21(14), 2726–2731 (2003).
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and Phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J. Clin. Oncol.21(24), 4489–4495 (2003).
   PubMed Web of Science ®Google Scholar
• Doolittle N, Miner M, Hall W et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood–brain barrier for the treatment of patients with malignant brain tumors. Cancer88(3), 637–647 (2000).
   PubMed Web of Science ®Google Scholar
• Khan R, Shi W, Thaler H, DeAngelis L, Abrey L. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J. Neuro-Oncol.58(2), 175–178 (2002).
   PubMed Web of Science ®Google Scholar
• Brevet M, Garidi R, Gruson B et al. First-line autologous stem cell transplantation in primary CNS lymphoma. Eur. J. Hematol.75(4), 288–292 (2005).
   PubMed Web of Science ®Google Scholar
• Abrey L, Moskowitz C, Mason W et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol.21(22), 4151–4156 (2003).
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J. Clin. Oncol.24(24), 3865–3870 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng T, Forsyth P, Chaudhry A et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant.31(18), 679–685 (2003).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Thiel E, Martus P et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J. Neurooncology80(2), 159–165 (2006).
   PubMed Web of Science ®Google Scholar
• Plotkin S, Betensky R, Hochberg F et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin. Cancer Res.10(17), 5643–5646 (2004).
   PubMed Web of Science ®Google Scholar
• Reni M, Mason W, Zaja F et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a Phase II trial. Eur. J. Cancer40(11), 168–168 (2004).
   Google Scholar
• Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer101(1), 139–145 (2004).
   PubMed Web of Science ®Google Scholar
• Enting R, Demopoulos A, DeAngelis L, Abrey L. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology63(5), 901–903 (2004).
   PubMed Web of Science ®Google Scholar
• Fischer L, Thiel E, Klasen H et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann. Oncol.17(7) 1141–1145 (2006).
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur. J. Hematol.70(4), 219–224 (2003).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Brugger W, Bamberg M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology54, 1707–1708 (2000).
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol.19(3), 742–749 (2001).
   PubMed Web of Science ®Google Scholar
• Nguyen P, Chakravarti A, Finkelstein D et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J. Clin. Oncol.23(17), 1507–1513 (2005).
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Oya N, Mizowaki T et al. Initial experiences of palliative stereotactic radiosurgery for recurrent brain lymphomas. J. Neuro-Oncol.77(1) 53–58 (2005).
   Google Scholar
• Lai RA, Lauren E, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology62(3), 451–456 (2004).
   PubMed Web of Science ®Google Scholar
• Monje M, Mizumatsu S, Fike J, Palmer T. Irradiation induces neural precursor cell dysfunction. Nat. Med.8, 955–962 (2002).
   PubMed Web of Science ®Google Scholar
• Omuro A, Ben-Porat L, Panageas K et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch. Neurol.62(10), 1595–1600 (2005).
   PubMed Web of Science ®Google Scholar
• Correa D, Anderson N, Glass A et al. Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings. Clin. Adv. Hematol. Oncol.1(8), 490 (2003).
   PubMedGoogle Scholar
• Fliessbach K, Helmstaedter C, Urbach H et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology647, 1184–1188 (2005).
   Google Scholar
• Ivers L, Kim A, Sax P. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein–Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin. Infect. Dis.38(11), 1629–1632 (2004).
   PubMed Web of Science ®Google Scholar
• Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer106(1), 128–135 (2006).
   PubMed Web of Science ®Google Scholar
• International Collaboration on HIV and Cancer. HAART and incidence of cancer in HIV infected adults. J. Natl Cancer Inst.92(22), 1823–1830 (2000).
   PubMed Web of Science ®Google Scholar
• Skiest D, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS17(12), 1781–1793 (2003).
   Google Scholar
• Jacomet C, Girard P-M, Lebrette M-G et al. Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS11(14), 1725–1730 (1997).
   PubMed Web of Science ®Google Scholar
• Forsyth P, Yahalom J, DeAngelis L. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology44, 1473–1479 (1994).
   PubMed Web of Science ®Google Scholar
• Bossolasco S, Falk KI, Ponzoni M et al. Ganciclovir is associated with low or undetectable Epstein–Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clin. Infect. Dis.42(4), 21–25 (2006).
   PubMed Web of Science ®Google Scholar
• Aboulafia D, Ratner L, Miles S, Harrington WJ. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium Pilot Study 019. Clin. Lymphoma Myeloma6(5), 399–402 (2006).
   PubMedGoogle Scholar
• Michelin S, del Rosario Perez M, Dubner D, Gisone P. Increased activity and involvement of caspase-3 in radiation-induced apoptosis in neural cells precursors from developing rat brain. Neurotoxicology25(3), 387–398 (2004).
   PubMedGoogle Scholar